A Study of JNJ-69086420, an Actinium-225-Labeled Antibody Targeting Human Kallikrein-2 (hK2) for Advanced Prostate Cancer
Janssen Research & Development, LLC
Janssen Research & Development, LLC
Plexium, Inc.
Acerand Therapeutics Limited
Eli Lilly and Company
Rondo Therapeutics
Nuvectis Pharma, Inc.
Astellas Pharma Inc
AdventHealth
University of Pennsylvania
M.D. Anderson Cancer Center
Instituto do Cancer do Estado de São Paulo
Fox Chase Cancer Center
Elevation Oncology
University of Chicago
Novartis
Nuvectis Pharma, Inc.
University of Pennsylvania
Memorial Sloan Kettering Cancer Center
German Cancer Research Center
Centre Hospitalier Universitaire Vaudois
Blueprint Medicines Corporation
Blueprint Medicines Corporation
Carisma Therapeutics Inc
Astellas Pharma Inc
Astellas Pharma Inc
Pfizer
Advaxis, Inc.
Morphotek
AO GENERIUM
Adaptimmune
Sumitomo Pharma America, Inc.
National Institutes of Health Clinical Center (CC)
H. Lee Moffitt Cancer Center and Research Institute
Cantargia AB
Blueprint Medicines Corporation
Karyopharm Therapeutics Inc
Novartis
Daiichi Sankyo
National Institutes of Health Clinical Center (CC)
Checkpoint Therapeutics, Inc.
Novartis
Northwell Health
AbGenomics B.V Taiwan Branch
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Memorial Sloan Kettering Cancer Center
Cedars-Sinai Medical Center
Novartis
University of Utah
H. Lee Moffitt Cancer Center and Research Institute
Navidea Biopharmaceuticals